Podcast Beta
Questions and Answers
What is the primary mechanism by which L form anticoagulants exert their effects?
What is the target PT/INR range for dosing L form anticoagulants?
Which of the following adverse effects is associated with the use of Ticlopidine?
Which medication is contraindicated during pregnancy due to its ability to cross the placenta?
Signup and view all the answers
What is the antidote for L form anticoagulants when reversal is necessary?
Signup and view all the answers
Which condition would most likely contraindicate the use of fibrinolytic agents?
Signup and view all the answers
What is the effect of aspirin on platelet activation?
Signup and view all the answers
Which of the following is NOT an indication for fibrinolytic agents?
Signup and view all the answers
What is the primary mechanism of action of heparin in anticoagulation therapy?
Signup and view all the answers
Which of the following statements about dosing and administration of low molecular weight heparins (LMWHs) is incorrect?
Signup and view all the answers
What is a common adverse effect associated with the use of anticoagulants?
Signup and view all the answers
Which condition is a contraindication for the use of heparin?
Signup and view all the answers
Which agent is used as an antidote for dabigatran in case of emergency?
Signup and view all the answers
The primary pharmacokinetic challenge associated with warfarin therapy is its:
Signup and view all the answers
Which clinical scenario best indicates the use of fondaparinux?
Signup and view all the answers
In the context of bleeding risk, which patient demographic is at higher risk when using anticoagulants?
Signup and view all the answers
What is the mechanism by which the direct acting thrombin inhibitors function?
Signup and view all the answers
What difference is noted between arterial and venous thrombus formation?
Signup and view all the answers
Upon which factor does the effectiveness of fibrinolysis primarily depend?
Signup and view all the answers
Which of the following statements regarding direct factor Xa inhibitors is true?
Signup and view all the answers
Which of the following combinations accurately describes a characteristic of enoxaparin?
Signup and view all the answers
What role does plasminogen play in the clotting cascade?
Signup and view all the answers
Study Notes
Coagulation Cascade
- The clotting cascade involves activating various clotting factors, which are inactive zymogens circulating in the blood.
- Activation occurs in a series, with each factor acting as a protease, activating the next.
- The process culminates in the conversion of fibrinogen to fibrin by thrombin.
- Factor Xa is responsible for this conversion.
- Drugs target different aspects of the cascade to manage clotting disorders.
Fibrinolysis
- Clots must dissolve once their purpose is fulfilled.
- Plasminogen is activated to its active form, plasmin, by tissue plasminogen activator (TPA).
Platelet Activation
- Platelet activation is critical for clotting.
- The process is triggered by tissue damage and involves the release of ADP, thromboxane A2, and serotonin.
- ADP stimulates platelet aggregation and the synthesis and release of thromboxane A2.
- Thromboxane A2 causes vasoconstriction and promotes thrombogenesis.
- Serotonin also contributes to vasoconstriction and further enhances platelet aggregation.
Arterial vs. Venous Blood Clotting
- Platelets play a pivotal role in thromboembolic disorders.
- In arteries, platelet aggregation occurs at damaged endothelium due to high pressure, forming a "white thrombus."
- As the arterial flow reduces, fibrin activates, resulting in a "red thrombus."
- Occlusion in arteries can cause ischemia.
- In veins, lower pressure allows for immediate fibrin activation following platelet aggregation, forming a long clot prone to detachment (DVT).
- DVT can embolize and lead to emboli formation in veins.
Anticoagulant Medications
- Anticoagulant medications are crucial in treating life-threatening conditions like stroke, MI, PE, DIC, and DVT.
- They work by various mechanisms, including fibrinolysis (clot busters) and inhibiting clotting mechanisms (anticoagulants and antiplatelet drugs).
- All anticoagulants can cause bleeding as a side effect.
Heparin and LMW Heparins
- Heparin amplifies the activity of antithrombin III (ATIII).
- Unfractionated heparin, low molecular weight heparins, and other heparin derivatives are available.
- Heparin is a heterogeneous mixture of sulfated mucopolysaccharides that activate ATIII.
- Activated ATIII inhibits thrombin (IIa), Xa and IXa by binding to them.
- Heparin speeds up this inhibition by binding to ATIII, causing a conformational change that enhances its activity.
- Heparin is not consumed in the process.
- Heparin's effectiveness varies due to its molecular heterogeneity. Some molecules lack the pentasaccharide sequence needed for efficient ATIII binding.
- High molecular weight molecules effectively inhibit all three clotting factors, while shorter chains primarily inhibit Xa.
- Dosage is adjusted to double the aPTT, with administration via intravenous (IV) or subcutaneous (subcu) routes.
- Low molecular weight heparins (LMWHs) are more predictable, with equal efficacy, increased bioavailability, and less frequent dosing.
- LMWHs include enoxaparin (Lovenox), dalteparin (Fragmin), tinzaparin (Innohep), and fondaparinux (Arixtra).
- Fondaparinux is synthetic and acts as a Xa inhibitor.
- Indications for heparin and LMWHs include DVT, DVT prophylaxis in high-risk groups, PE, and unstable angina.
Adverse Effects of Heparin and LMWHs
- Bleeding is the most significant adverse effect, particularly in elderly women and those with renal failure.
- Monitoring of aPTT is necessary with unfractionated heparin, while LMWH requires less monitoring in patients with normal renal function.
- Allergic reactions are possible due to the animal source of heparin.
- Long-term heparin use can lead to osteoporosis and mineralocorticoid deficiency.
- Thrombocytopenia is a potential side effect, often transient, but can be severe in 5% of cases.
- Heparin-induced thrombocytopenia (HIT) involves an antibody complex that binds to platelets, causing platelet aggregation, thromboembolism, and platelet destruction.
- Platelet counts should be monitored.
- HIT necessitates discontinuation of heparin and treatment with HIT drugs.
- Contraindications include history of allergy, active bleeding, hemophilia, thrombocytopenia, intracranial hemorrhage, ulcers, and severe renal or liver disease.
Protamine Sulfate
- Protamine sulfate is the antidote for heparin.
- It binds to heparin and inactivates its activity.
- It can also neutralize LMWH, but not completely.
- Protamine sulfate is effective for enoxaparin, but not for fondaparinux.
Direct Thrombin Inhibitors
- Direct thrombin inhibitors bind directly to thrombin.
- They are used to treat HIT and include drugs like lepirudin, dabigatran, argatroban, bivalirudin.
- Lepirudin and bivalirudin effectively manage HIT, while argatroban is metabolized by the liver and effective in patients with HIT.
- Argatroban's dose is reduced in liver failure and interferes with INR testing.
- Dabigatran is a newer oral drug.
- Idarucizumab acts as an antidote to dabigatran.
Direct Xa Inhibitors
- Direct Xa inhibitors, including rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa), are oral medications that directly bind to Xa.
- They are useful for clot prevention in atrial fibrillation (A-fib).
- Andexxa is a reversal agent that acts as a decoy factor Xa to bind to drugs.
Rivaroxaban (Xarelto)
- Rivaroxaban does not affect thrombin or platelets.
- Indications include DVTs and PE.
Apixaban (Eliquis)
- Apixaban is a Xa inhibitor approved for stroke and emboli prevention in non-valvular A-fib.
- It is not recommended for individuals with prosthetic heart valves.
- Bleeding is a potential adverse effect.
Edoxaban (Savaysa)
- Edoxaban is approved for stroke and emboli prevention in non-valvular A-fib.
- It is also used for DVT and PE.
Coumarins
- Warfarin is a highly plasma protein-bound drug eliminated by the CYP 450 system.
- It has a long half-life (36 hours) and a narrow therapeutic index.
- Warfarin is a racemic mixture of D and L forms, with the L form being more potent.
- Mechanistically, warfarin inhibits vitamin K activation, which is required for the synthesis of clotting factors II, VII, IX, and X.
- This effect has a 12-hour delay, allowing for the use of available clotting factors for a short period.
- Warfarin is contraindicated in pregnancy as it crosses the placenta.
- Bleeding is a significant adverse effect.
- Dosing is adjusted to achieve a PT/INR of 2.5-3.5.
- Warfarin is indicated for thromboembolic event prophylaxis from A-fib or valve replacement, DVT/PE prevention, and post-MI.
Interactions with Warfarin
- Warfarin interacts with numerous drugs.
- Vitamin K acts as an antidote.
- Stop the drug and administer vitamin K.
- Fresh frozen plasma or factor VIIa can be used for a more rapid reversal.
Antiplatelet Drugs
- These medications target platelet activation, crucial for clots causing occlusion in arterial blood.
- They are primarily used for TIA, post-MI, and preventing clots in coronary arteries associated with indwelling devices or procedures.
- They are generally not used for conditions affecting venous blood like DVTs and PEs.
Aspirin (ASA)
- Aspirin irreversibly inhibits cyclooxygenase, blocking the synthesis of TXA2.
Clopidogrel (Plavix) and Ticlopidine (Ticlid)
- Clopidogrel and ticlopidine irreversibly inhibit the ADP receptor on platelets, reducing aggregation.
- They are used for TIA prophylaxis, unstable angina, and placement of coronary stents.
- Adverse effects include:
- Ticlopidine: leukopenia (requiring monitoring), hemorrhage, nausea, and diarrhea.
- Clopidogrel: thrombotic thrombocytopenic purpura, a serious condition characterized by disseminated clots in small vessels.
Platelet GpIIb/IIIa Receptors
- Cilostazol (Pletal) inhibits platelet aggregation, while eptifibatide (Integrilin), tirofiban (Aggrastat), and abciximab (Reopro) block IIb receptor occupancy.
- Abciximab is a monoclonal antibody against IIb/IIIa.
- These drugs are mostly used during angioplasty procedures.
- Cilostazol is oral and used for intermittent claudication, while the others are administered intravenously and utilized primarily during angioplasty.
Fibrinolytic Agents
- These medications all activate plasmin to dissolve existing clots.
- They are used for life-threatening clots and must be administered within 6 hours of the thrombotic event.
- They act quickly but have short half-lives.
- Tissue plasminogen activators: alteplase, reteplase, and tenecteplase, along with urokinase and streptokinase, convert plasminogen to plasmin.
- Indicated for: recent acute MI, PE, severe DVT, and thromboembolic stroke (tPA only).
- Contraindications and cautions:
- Risk of bleeding: hemorrhagic conditions, risk of hemorrhagic stroke, recent surgery (10 days), GI bleed within 3 months, pregnancy, HTN with elevated diastolic pressure, and aortic dissection.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Related Documents
Description
This quiz covers the key concepts of the coagulation cascade, fibrinolysis, and platelet activation crucial for understanding blood clotting processes. It explores the activation of clotting factors, the role of thrombin, and the mechanisms behind clot dissolution. Test your knowledge on how these processes interact to maintain hemostasis.
